BRYNN CLYMER: Open Payments
NPI 1912281270 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,209 in 55 payments from 17 companies in 2025. Trend: 2023 $522 · 2024 $842 · 2025 $1,209
Food & beverage: $1,119Education: $90
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $349 |
| Verona Pharma, Inc. | 9 | $153 |
| GENZYME CORPORATION | 5 | $91 |
| SANOFI-AVENTIS U.S. LLC | 1 | $90 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| ANI Pharmaceuticals, Inc. | 2 | $57 |
| United Therapeutics Corporation | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
Products named: NUCALA, DUPIXENT, Ohtuvayre, OFEV, TRELEGY ELLIPTA, PURIFIED CORTROPHIN GEL, Tyvaso, GLASSIA.
Industry payments across TX — which companies pay providers there.
